StockNews.AI
MRNA
StockNews.AI
18 days

UK Court of Appeal Confirms Moderna's EP'949 Patent is Valid and Infringed by Pfizer/BioNTech

1. UK Court upholds Moderna's EP'949 patent, confirming Pfizer infringement.

2m saved
Insight
Article

FAQ

Why Bullish?

The patent victory strengthens Moderna's competitive position against Pfizer, potentially boosting future revenues. Historical data shows legal victories in biopharma enhance stock values significantly.

How important is it?

The ruling reinforces MRNA's patent portfolio, which is critical to achieving market supremacy and sustaining investor confidence.

Why Short Term?

Immediate market reaction expected as investors respond to patent protection news, influencing MRNA stock prices quickly.

Related Companies

PFEBNTX
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent. This decision affirms the High Court's initial ruling from July 2024 that the EP'949 patent is valid and infringed by Pfizer/BioNTech's COVID-19 vaccine, Comirnaty®, which was subsequently appealed by Pfizer/BioNTech.

Related News